Effectiveness of karxt (xanomeline-trospium) for cognitive impairment in schizophrenia: post hoc analyses from a randomised, double-blind, placebo-controlled phase 2 study

HIGHLIGHTS

• who: Colin Sauder from the (UNIVERSITY) have published the research: Effectiveness of KarXT (xanomeline-trospium) for cognitive impairment in schizophrenia: post hoc analyses from a randomised, double-blind, placebo-controlled phase 2 study, in the Journal: (JOURNAL) of 23/05/2022
• what: The approach taken in this study could be implemented in a similar but prespecified fashion in future CIAS studies, using extreme variability across subtest performance in combination with other stability criteria (e_g, a limit on change in performance across baseline and screening assessments) to exclude patients prospectively. This study had limitations inherent to . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.